

NURITAS

Life-changing Discoveries

Discovery on Demand

Corporate Overview

- Nuritas deploy multiple technologies to revolutionise and accelerate drug discovery in areas defined by our collaborating partners
 - Convergence of computational approaches with wet sciences ('omics) rapidly and efficiently predict patentable peptides with desired characteristics
 - Starting with natural & safe sources, our AI identifies inherently low toxicity drug backbones for further synthetic development
 - Globally our data is unique & proprietary – yielding insights like no others
 - Our approach has been proven & validated by global leaders
- Privately held, founded in 2014
 - Backing from
 - ❖ New Protein Capital
 - ❖ Ali Partovi (Facebook & Dropbox)
 - ❖ U2's Bono and The Edge
 - ❖ Salesforce CEO Marc Benioff



Nestlé **BASF**


The Peptide Revolution- Why Now?

- Urgent need to push boundaries of traditional drug design & discover innovative molecules to modulate/cure disease
- Peptides, as natural intrinsic signalling molecules, hold such promise
- Natural safe sources of peptides, co evolved with man, offer reservoir of new low toxicity drug candidates (safer/green/sustainable)
- Technology advances can now mine billions of once hidden actives for desired characteristics
- Prior liabilities now less problematic due to advances in synthetic chemistry, formulation (pharmacokinetics, $T_{1/2}$, stability, solubility)


The Promise of Peptides beyond “Traditional” Peptide Therapies

- Unique properties- molecularly poised between small molecules & biologics - new promise as candidates against “undruggable”, intracellular targets
- New peptides in clinic already extending beyond traditional treatment modalities
 - ✓ protein-protein interactions,
 - ✓ target receptor tyrosine kinases
 - ✓ inhibit intracellular target


Compact Binding: Small Molecule Inhibitor



Extended Binding via Peptide



- Using AI as the compass- Nuritas locate, target and unlock desired and specific actives from:
 - selected sources (natural parent)
 - for synthetic strategies (synthetic homologue)
 - to improve characteristics (modification/optimisation strategies)
- Each step is guided/accelerated via technology and validated via traditional experimental laboratory methodologies (fully integrated approach)
- Nuritas proprietary platforms (Nπφ™) draw from multiple technology stacks and AI approaches to
 - Define disease area (Target)
 - Predict new theoretical drugs (Predict)
 - Specifically unlock from source via AI informed proprietary process (Unlock)
 - Optimisation/modification strategies for improved properties (enabled by In Silico design)
- Using data **proprietary** to Nuritas, our AI can analyse billions of molecules and peptides to predict and identify how they impact specific health areas and disease aspects.



Nuritas Industry Focus & Discovery Models

Dermatology, Consumer



Pharmaceuticals




Discovery On Demand



Industry Focus

A green apple is the central focus, with a white outline of a hexagon containing the word 'PREDICT' and a 'TARGET UNLOCK' icon below it. The background is a dark blue with faint binary code.

Models

A green apple is the central focus, with a white outline of a hexagon containing the word 'PREDICT' and a 'TARGET UNLOCK' icon below it. The background is a dark blue with faint binary code.

Smart Agriculture



Functional Ingredients




Already Discovered Pipeline

Discovery on Demand

Flexible and Adaptable

Nuritas On Demand Responds to Industry Needs
Our AI Platforms are flexible and adaptable to multiple disease areas and industry defined discovery challenges



Bubble Size: Large: existing in house discovery programs, Small: emerging in house discovery programs

Fully Integrated- End to End Discovery

Engage across the entire spectrum : in silico discovery-pre clinical validation

Benefits: Progression of “best chance” candidates to clinic (cost, time, clinical relevance)

Improve Success of Existing In House Programs with new candidates

Or

Provide new discovery pipelines for new discovery strategies/diseases

1

Natural Parent Peptide

- Starting blocks of low inherent toxicity (improved basal tox/safety)
- Synthetic modifications improve characteristics

2

Potential to test natural parent **in humans** under food regulated “clinical trails”: cost & candidate selection pre Pharma Clinical Trials

3

Cost Effective Innovation

Platform can identify peptides ten times faster and 500 times more accurately (cost, time, efficacy benefit)

4

High Speed & Evolving Predictions

Machine learning permits AI evolution for greater predictive ability

5

Novel Product Differentiation

Every bioactive peptide Nuritas discovers is novel and patentable

6

Proven Model


Proven validated model with industry partners

First Nuritas AI discovered ingredient to be commercialised by partner by year end

Current Disease Areas



Future Areas of Interest (via Industry Collaborations)



Future Discovery Strategies (via Industry Collaborations)



AI Benefit



✓ **Complicated Diseases**

✓ **Complicated Data**

Collaboration

Collaboration both parties leverage competencies and strengths to discover-develop drugs

Deal Milestones

Payments staggered and based on the success of development milestones



Upfront Payments

Upfront payment adjusted to provide a trade-off mechanism for royalties using a net present value calculation

Royalties

Royalty percentages can be negotiated to reflect the value and probability of success of the drug candidates

To find out more about our
Discovery on Demand service,
please contact

Chantelle Kiernan
Director Lifesciences

Nuritas
Kiernan.Chantelle@Nuritas.com

Headquarters and Lab

Dublin, Ireland

Tel: +353-(0)1-430-1290

Mob: +353 (87)- 760-0815

www.nuritas.com

twitter.com/NuritasResearch

